New drug A3907 tested for rare liver disease, study halted early
NCT ID NCT05642468
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a drug called A3907 in 18 adults with Primary Sclerosing Cholangitis (PSC), a rare liver disease. The goal was to check if the drug is safe and how the body processes it. The study was stopped early, so results are limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY SCLEROSING CHOLANGITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ASST Grande Ospedale Metropolitano Niguarda
Milan, Italy
-
ASST di Monza - Azienda Ospedaliera San Gerardo
Monza, 20900, Italy
-
Azienda Ospedale Università Padova
Padova, 35128, Italy
-
Centrum Medyczne INTER-MED
Częstochowa, Poland
-
Hopital Saint Antoine
Paris, 75012, France
-
Hospital Clinic de Barcelona
Barcelona, 8036, Spain
-
ID Clinic Arkadiusz Pisula
Mysłowice, Poland
-
Uniwersyteckie Centrum Kliniczne im. Prof. Kornela Gibinskiego
Katowice, Poland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a common drug stop a rare liver disease from returning after transplant?
- New antibody aims to tame rare liver disease
- Could a fecal transplant help treat a rare liver disease?
- Poop pills could tame rare liver disease
- Antibiotic vancomycin tested as PSC treatment – trial stopped early
- New hope for rare liver disease: experimental drug CS0159 enters Mid-Stage trial